Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA May Request "Intermediate" Enforcement Authority For Clinical Trials

Executive Summary

FDA is considering asking Congress for authority to bring intermediate enforcement actions in response to violations of human research regulations in clinical trials, FDA Office of Regulatory Affairs Director of Enforcement Daniel Michels told the House Government Reform/Human Resources Subcommittee May 3.

You may also be interested in...



FDA Civil Penalties For Human Subject Violations Considered By Kennedy

Legislation granting FDA the authority to levy civil monetary penalties against researchers and institutions violating federal human subjects protections could be introduced by Sen. Kennedy (D-Mass.) before the end of the year.

FDA Civil Penalties For Human Subject Violations Considered By Kennedy

Legislation granting FDA the authority to levy civil monetary penalties against researchers and institutions violating federal human subjects protections could be introduced by Sen. Kennedy (D-Mass.) before the end of the year.

Trial Recruiting, IRBs Could Be Upcoming Congressional Hearing Topics

A hearing to discuss FDA and NIH progress in complying with HHS Inspector General recommendations on institutional review boards is being planned for early May by House Government Reform/Criminal Justice, Drug Policy & Human Resources Subcommittee Chairman Mica (R-Fla.).

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel